Stephan Ludwig

Von Esmarch Str. 56
Muenster, NW 48149, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 168 publications

Divergent granulopoiesis at extramedullary sites safeguards antibacterial host defense.

Divergent granulopoiesis at extramedullary sites safeguards antibacterial host defense.

Journal: Science immunology

Published: April 17, 2026

The activation of the metabolic oxaloacetate-pyruvate axis restores influenza A virus replication during impaired glycolysis.

The activation of the metabolic oxaloacetate-pyruvate axis restores influenza A virus replication during impaired glycolysis.

Journal: Virology journal

Published: December 16, 2025

Integrated in silico and in vitro approaches reveal novel coumarin hybrids targeting influenza A virus RNA-dependent RNA polymerase.

Integrated in silico and in vitro approaches reveal novel coumarin hybrids targeting influenza A virus RNA-dependent RNA polymerase.

Journal: European journal of medicinal chemistry

Published: December 12, 2025

MEK1/2 inhibitor ATR-002 reshapes host transcriptome and modulates immune regulatory genes in SARS-CoV-2 infection.

MEK1/2 inhibitor ATR-002 reshapes host transcriptome and modulates immune regulatory genes in SARS-CoV-2 infection.

Journal: Frontiers in immunology

Published: October 13, 2025

Inhibitors of cellular RSK isoforms exhibit anti-SARS-CoV-2 activity, enhance efficacy of direct-acting antivirals, and suppress emergence of resistance.

Inhibitors of cellular RSK isoforms exhibit anti-SARS-CoV-2 activity, enhance efficacy of direct-acting antivirals, and suppress emergence of resistance.

Journal: Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy

Published: September 07, 2025

Controlling the Sulfation Density of Glycosaminoglycan Glycopolymer Mimetics Enables High Antiviral Activity against SARS-CoV-2 and Reduces Anticoagulant Activity.

Controlling the Sulfation Density of Glycosaminoglycan Glycopolymer Mimetics Enables High Antiviral Activity against SARS-CoV-2 and Reduces Anticoagulant Activity.

Journal: Biomacromolecules

Published: July 07, 2025

Challenges of broad-spectrum antiviral drug discovery and development for emerging pathogens.

Challenges of broad-spectrum antiviral drug discovery and development for emerging pathogens.

Journal: Drug discovery today

Published: June 18, 2025

Antiviral and immunomodulatory effect of zapnometinib in animal models and hospitalized COVID-19 patients.

Antiviral and immunomodulatory effect of zapnometinib in animal models and hospitalized COVID-19 patients.

Journal: Frontiers in immunology

Published: May 20, 2025

SARS-CoV-2 Variant-Specific Antibodies in Vaccinated Inflammatory Bowel Disease Patients.

SARS-CoV-2 Variant-Specific Antibodies in Vaccinated Inflammatory Bowel Disease Patients.

Journal: Vaccines

Published: April 22, 2025

Influenza H5Nx viruses are susceptible to MEK1/2 inhibition by zapnometinib.

Influenza H5Nx viruses are susceptible to MEK1/2 inhibition by zapnometinib.

Journal: Emerging microbes & infections

Published: February 20, 2025

Influenza A virus NS1 suppresses nuclear speckles promoted gene expression by inhibition of transcription.

Influenza A virus NS1 suppresses nuclear speckles promoted gene expression by inhibition of transcription.

Journal: Npj viruses

Published: January 23, 2025

Host-targeted antivirals against SARS-CoV-2 in clinical development - Prospect or disappointment?

Host-targeted antivirals against SARS-CoV-2 in clinical development - Prospect or disappointment?

Journal: Antiviral research

Published: December 29, 2024

Showing 1-12 of 168

Last Updated: 09/26/2026